Objectives: Previous trials in adults with impaired immunity and respiratory failure suggest that early noninvasive ventilation avoids endotracheal intubation and improves survival. No randomized clinical trials have addressed this question in children.
Design:
We undertook an open, parallel-group randomized trial in three pediatric hospitals. Subjects: Children with impaired immunity and acute respiratory failure defined as tachypnoea (> 90th centile); a new requirement for supplemental oxygen; and new chest radiograph infiltrates. Interventions: Children were randomly assigned to early PICU admission for continuous positive airways pressure (early continuous positive airways pressure) or to standard care. The primary outcome was endotracheal intubation by 30 days. Measurements and Main Results: One-hundred fourteen children met inclusion criteria of whom 42 were randomized between January 2013 and January 2016. There was no significant difference in endotracheal intubation by 30 days with early continuous positive airways pressure (10/21; 48%) compared with standard care (5/21; 24%), odds ratio 2.9 (0.8-10.9), p value equals to 0.11. However, 30-day mortality was significantly higher with early continuous positive airways pressure (7/21; 33%) compared with standard care (1/21; 5%), odds ratio 10.0 (1.1-90.6), p value equals to 0.041. Mortality at 90 days was early continuous positive airways pressure (11/21; 52%) versus standard care (4/21; 19%), odds ratio 4.7 (1.2-18.6), p value equals to 0.029, whereas mortality at 1 year was similar early continuous positive airways pressure (13/21; 61.9%) versus standard care (9/21; 42.7%), odds ratio 2.2 (0.6-7.4), p value equals to 0.22. There were two serious adverse events: early continuous positive airways pressure (pneumothorax) and standard care (hemothorax). Conclusions: This study provided no evidence to support early PICU admission for continuous positive airways pressure in children with acute respiratory failure and impaired immunity. There was a trend toward increased endotracheal intubation and a higher early mortality in the early continuous positive airways pressure group. (Pediatr Crit Care Med 2018; 19:939-948) Key Words: acute respiratory distress syndrome; immunodeficiency continuous positive airways pressure; noninvasive ventilation; pediatric intensive care unit respiratory failure C hildren with impaired immunity represent an increasing subset of PICU admissions. The wider use of immunosuppressive medications and improved survival of children with congenital and acquired immunodeficiencies means that this trend is likely to continue. Observational data show consistently worse outcomes for these children especially in the context of acute respiratory failure-for example, in pediatric acute respiratory distress syndrome (ARDS), overall mortality is around 20% (1), but in the context of impaired immunity, this approaches 50% (2, 3) .
The association of "invasive" mechanical ventilation with death in adults with impaired immunity prompted a number of studies to determine if noninvasive ventilation could avoid endotracheal intubation and reduce mortality. Three small randomized clinical trials (RCTs) of adults with acute respiratory failure and impaired immunity suggest that using continuous positive airways pressure (CPAP), via facemask or helmet, "before" it is required to maintain gas exchange, reduces the risk of death by around 60% (4) (5) (6) .
None of these studies, however, included children, a group in whom the risks and benefit may differ. Inferences from the adult trials may not be appropriate to children because of differences in respiratory mechanics (including functional residual capacity being closer to closing volume), differences in case mix (both in the causes of respiratory failure and the nature of the impaired immunity), but also in the challenges of administering effective CPAP to young children. A further challenge was a lack of data on the incidence and outcome of acute respiratory failure in children with impaired immunity who do not progress to intensive care admission.
We performed a pragmatic RCT to test the hypotheses that early admission to PICU for CPAP would 1) decrease the need for endotracheal intubation for invasive mechanical ventilation and 2) improve the outcomes of acute respiratory failure in infants and children with impaired immunity.
METHODS
We undertook an open, parallel-group RCT between January 2013 and January 2016 in three children's hospitals with large bone marrow transplant programs in the United Kingdom. Research ethics committee approval was obtained from the National Research Ethics Service Committee LondonRiverside (reference 12/LO/1051). The protocol was registered prior to trial opening (ISRCTN82853500) and is available as an electronic supplement (Supplemental Digital Content 1, http://links.lww.com/PCC/A718). The study was funded by Great Ormond Street Hospital Children's Charity (Registered Charity Number 235825).
Participants
Children aged less than 18 years with impaired immunity (as a result of a primary diagnosis, therapy, or a combination of both-see full protocol in electronic supplement, Supplemental Digital Content 1, http://links.lww.com/PCC/A718) expected to last for at least 3 months and who developed acute (or acute on chronic) respiratory failure were eligible for the study.
Importantly, the standard of care in the participating units (and in U.K. healthcare system in general) is to admit to intensive care only when organ support is thought to be necessary. Children are not typically admitted for "observation."
Acute respiratory failure was defined by the following:
1) new onset of "hypoxemia": peripheral oxygen saturation (Spo 2 ) less than 90% in air; 2) "tachypnea": greater than 90th centile for age unless receiving an opiate infusion-(respiratory rate 55 < 12 mo, 45 12 mo to < 2 yr, 30 ≥ 2 yr to < 4 yr, 25 ≥ 4 yr to < 10 yr, and 20 ≥ 10 yr to < 18 yr); and 3) new or increased pulmonary infiltrates on chest radiograph developing within 48 hours.
Acute on chronic respiratory failure was defined by the following:
1) an increase of more than 20% above baseline supplemental oxygen; 2) an increased respiratory rate; and 3) new or increased pulmonary infiltrates on chest radiograph.
The cause of acute respiratory failure was not relevant to eligibility for the study. Recruitment within 24 hours of meeting all three criteria was required. Potential study participants were identified by hospital ward staff in collaboration with intensive care outreach teams who alerted the research study teams.
Exclusion criteria were ongoing receipt of invasive mechanical ventilation for nonrespiratory indications; emergency PICU admission for invasive mechanical ventilation for other conditions independent of the degree of acute respiratory failure, for example, for shock, reduced level of consciousness, or seizures, as deemed by the PICU team; recent oesophageal/gastric surgery; end-of-life care plan in place with limitation of resuscitation; life expectancy less than 12 months; and already receiving care on the PICU. Formal written consent was obtained from parents prior to inclusion in the study.
Randomization
Participants were allocated 1:1 to early CPAP (intervention group) or standard care (control group) using a secure, web-based, randomization system (www.sealedenvelope. com). Minimization was performed on age (< 12 mo/≥ 12 mo) and on bone marrow transplantation status (yes/ no). Each participant was allocated with 80% probability to the group that minimized between-group differences in these factors among all participants recruited to the trial to date and to the alternative group with 20% probability.
Procedures
Four levels of respiratory support were defined ( Fig. 1A) (level 1-inspired oxygen therapy on the ward; level 2-CPAP at 6-10 cm H2O; level 3-noninvasive bilevel positive airway pressure (BiPAP); and level 4-endotracheal intubation and mechanical ventilation). High flow nasal cannula (HFNC) oxygen was not permitted in the context of this study.
Participants allocated to the intervention group were admitted to the PICU to receive CPAP (level 2 respiratory support) of at least 6 cm H 2 O with supplemental oxygen for a minimum of 12 hours per day for 4 consecutive days. The interface for delivering CPAP and all other care was determined by the primary PICU clinical team.
Participants allocated to the standard care group remained on the ward and received supplemental oxygen (level 1 respiratory support) to maintain oxygen saturation in accordance with standard local practice. The choice of oxygen delivery system and dose were determined by the primary ward clinical team as were all other aspects of care.
Participants remained on CPAP or supplemental oxygen unless they either met prespecified criteria for escalation or developed another condition (e.g., shock or encephalopathy) that required endotracheal intubation and invasive mechanical ventilation. A, Four levels of respiratory support were described. Decision to escalate between levels was protocolized. Settings within each level were at the discretion of clinical staff as were decisions to deescalate to a lower level (other than deescalation from continuous positive airways pressure [CPAP] in the intervention group which was required to be delivered for 4 d for a minimum of 12 hr). B, The maximum level of respiratory support received by participants in each group. Intervention group: five cases progressed through all levels of respiratory support, and five were intubated for acute indications (shock, seizure, etc.).
a In two cases no ICU bed was available within 24 hr and cases remained on the ward. Control group: two were intubated following stepping up through all four levels of respiratory support, and three were intubated for acute indications. BiPAP = bilevel positive airway pressure, CXR = chest radiograph. Briefly, criteria for escalation were as follows (see full protocol in electronic supplement, Supplemental Digital Content 1, http://links.lww.com/PCC/A718): respiratory acidosis (defined as an increase in Pco 2 accompanied by a pH ≤ 7.20 for more than 1 hr); persistent moderate hypoxemia (defined as either a Pao 2 :Fio 2 < 85 mm Hg [11.3 kPa] or Spo 2 :Fio 2 < 98 mm Hg for more than 1 hr or Spo 2 < 90% for more than 1 hr despite optimized therapy); severe hypoxemia (defined as failure to maintain Spo 2 > 80% at any time); evidence of persistent inadequate oxygen delivery (defined as an increase in serum lactate or superior caval vein oxygen saturation persistently < 65%).
Although the criteria to escalate support or to go directly to endotracheal intubation and invasive mechanical ventilation were protocolised, decisions to step-down respiratory support were at the discretion of the clinical team (aside from a step-down from level 2 to level 1 for the intervention group which was not permitted before the end of the 4-d intervention period). "The choice of respiratory support settings within each of the four levels (e.g., the choice of CPAP or BiPAP settings) was at the discretion of the clinical team."
Outcomes
The primary outcome was endotracheal intubation and invasive mechanical ventilation (level 4 respiratory support) within 30 days post randomization.
Secondary outcomes were within 30 days of randomization; mortality, days free from any ventilatory support, maximum and aggregate Pediatric Logistic Organ Dysfunction (PELOD) score, receipt of level 2 or level 3 respiratory support, and days free from supplemental oxygen (above preacute respiratory failure); and hospital, 90-day and 1-year mortality.
Sample Size Calculation
Using U.K. Pediatric Intensive Care Audit Network data, 75% of PICU admissions with impaired immunity and acute respiratory failure received endotracheal intubation for invasive mechanical ventilation. No accurate estimates for oxygen use in children with impaired immunity on the ward were available. From discussions with ward staff, we estimated that approximately twice as many children received oxygen on the ward as were admitted to PICU. Therefore, we anticipated an endotracheal intubation rate of approximately 35-40% in the control group. Using a similar relative risk reduction (~60%) as reported in the adult RCTs, we anticipated a decrease in the endotracheal intubation rate from 35% to 14%. A sample of 148 children (74 in each group) would be required to detect with 80% power and a type 1 error rate of 5% (two sided).
Statistical Analysis
Analyses were specified and lodged a priori according to a statistical analysis plan (see electronic supplement, Supplemental Digital Content 2, http://links.lww.com/PCC/A719). All analyses were conducted by intention-to-treat, with a two-sided p value of less than 0.05 taken to indicate a statistically significant result. The primary effect estimate was the relative risk of endotracheal intubation for invasive mechanical ventilation at 30 days post randomization, with statistical significance assessed by Fisher exact test.
As a secondary analysis, the primary outcome was also analyzed by multivariable logistic regression adjusted for baseline covariates of age, chronic diagnosis, bone marrow transplantation, suspected cause of acute respiratory failure, weight for age z score (using the British 1990 growth reference), and Pediatric Index of Mortality 2 (2016 recalibration). The baseline covariates were selected a priori for their anticipated strong association with the outcome, no further selection of covariates was performed based on imbalance at baseline, or significance in univariable analyses.
Secondary outcomes were analyzed by logistic regression for binary outcomes (mortality, receipt of level 2/3 respiratory support) or linear regression for continuous outcomes (PELOD, days free from ventilatory support/supplemental oxygen) adjusted for the same baseline covariates as above. Due to the small sample size, no subgroup analyses were planned. Requests for sharing of deidentified participant data will be considered by the investigators.
RESULTS
Between January 7, 2013, and January 31, 2016, 114 children who met inclusion criteria were identified on screening, 19 of these met one or more exclusion criteria, and 42 were recruited to the study (Fig. 2) and followed for 1 year. No participants were lost to follow-up. Baseline characteristics were similar in both groups (Table 1) . Notably, 20 of 42 participants (48%) were admitted following a bone marrow transplant.
Recruitment was approximately one third of anticipated resulting, in part, from an overestimation of oxygen use on the ward and relatively low levels of consent to participate. At review after 19 months the Trial Steering Committee made a decision, supported by the Data Monitoring Committee and funder, to continue recruitment to the end of the original, planned, 3-year period but not to extend beyond this date. This decision was based on four factors: a lack of safety concerns; recognition of the incorrect assumptions contributing to the power calculation and recruitment targets; the value of "any" trial data in this highrisk population since none were available; and a recognition that extending the trial may be problematic because of evolving practice including the use of HFNC therapy.
Two of the 21 participants in the early group were not admitted to PICU because of lack of bed availability ( Table 2) . Of the 19 admitted, 18 received CPAP-although only 11 completed CPAP for the prescribed minimum allocation of 4 days of at least 12 hours of CPAP. These protocol deviations were principally because of perceived discomfort with CPAP. HFNC oxygen was administered outside of the protocol to four participants in the intervention group and to three in the control group. 
Primary Outcomes
Endotracheal intubation for invasive mechanical ventilation within 30 days in the early CPAP group was double that for the standard care group (10/21, 47.6% vs 5/21, 23.8%; relative risk, 2.00; 95% CI, 0.82-4.86; p = 0.11) (Table 3, Fig. 1B, and  Fig. 3 ). This was not altered by adjustment for the prespecified baseline covariates (Table 3) .
Secondary Outcomes
Mortality at 30 days, at 90 days, and at hospital discharge was significantly higher in the early CPAP group whereas 1-year mortality was similar for both groups (Table 3 and Fig. 4) . These findings persisted following adjustment for covariates. Receipt of level 2 or level 3 respiratory support and days alive and free from ventilatory support or supplemental oxygen were similar for both groups. Maximum and aggregate PELOD scores in the first 30 days trended toward being greater in the intervention group-and were significant following adjustment for covariates.
Adverse Events
Adverse events were rare-one pneumothorax was reported in the intervention group and one hemothorax in the control group.
DISCUSSION
Study of Early CPAP in Acute Respiratory Failure (SCARF) is the only RCT performed to date in children with the high-risk combination of impaired immunity and acute respiratory failure. We found no evidence that a strategy of early PICU admission for CPAP was a superior approach to the management of acute respiratory failure in children with severely impaired immunity. Indeed, this strategy may have contributed to an increased early mortality. In addition to informing on a lack of benefit from early PICU admission for CPAP in this population, this study reinforces the overall high mortality for this population-50% (21/42) at 1 year.
This trial has a number of weaknesses. First, it is significantly underpowered for the primary outcome. A major contributor to this was the lack of data on ward level oxygen use in each institution (or in the literature), meaning that the assumptions underpinning the sample size calculation were incorrect. The introduction of electronic databases of vital sign observations means that this should be avoidable in the future. Second, our definition of respiratory failure was not a validated measure, but rather sought to identify the earliest point at which a reasonable body of pediatric intensivists might consider using CPAP. Third, adherence to the CPAP protocol was challenging either due to a lack of PICU bed availability or, predominantly, to intolerance of a facemask. The intention-to-treat analysis, however, likely provides a "real-life" comparison of the clinical effectiveness of these two strategies (rather than a narrower efficacy study). Fourth, the choice of primary outcome measure could be criticized. Endotracheal intubation was chosen, as it had been used in previous RCTs in this field (4-6), and was anticipated to have a higher event rate than mortality while closely associated with it. The potential problem with endotracheal intubation rate is that both part of the intervention and the outcome are determined by the clinical team. Fifth, with this sample size and the lack of a suitable validated severity-of-illness measure outside of the ICU, we cannot exclude the CPAP group being more unwell at baseline. Finally, reflecting on the design of this RCT in 2012, HFNC oxygen was not assessed in the study as its use was not commonplace at this time. We are very aware of the importance of this question. We have recently completed a randomized controlled feasibility trial comparing HFNC oxygen (7). However, Chalmers et al (8) remind us of the importance of reporting of all trial data. Perhaps this is especially true when there are no other data for comparison.
This RCT, however, has the following strengths. First, it is a formal, multicentre RCT following Consolidated Standards of Reporting Trials guidance with a preregistered protocol and statistical analysis plan. Such studies are relatively rare in critically ill children. Second, the results are consistent across all outcome measures with standard care either superior to early CPAP or trending in that direction. Third, the Fragility Index for SCARF is 10 (9)-meaning all 10 patients who received endotracheal intubation in the early CPAP group would have had to avoid this for the study to suggest superiority of CPAP as a recommended approach.
Recent work in adults has similarly failed to show an advantage for noninvasive ventilation. The IVNIctus trial which recruited around 350 adults with hematological or solid cancers suggested equivalence for early noninvasive ventilation (NIV) with oxygen therapy alone (10) . The Efraim multinational prospective cohort study of immunocompromised adults with acute hypoxemic respiratory failure also found no reduction in intubation or mortality with NIV. Interestingly, HFNC was associated with a reduction in need for intubation, but not mortality (11) . NIV failure is consistently associated with poor outcome (12, 13) . Noninvasive ventilation is being discouraged in this population (14) . To this end, our data are not surprising in this context.
The important unanswered question is "why was early CPAP not superior?" In answering this, both the impact of CPAP use and early admission to PICU have to be considered as both were part of the intervention. Might CPAP have had a direct deleterious effect? This seems unlikely given the data supporting positive end-expiratory pressure (PEEP) (15) . However, overdistension can certainly be harmful in healthy Median ( In two cases, a PICU bed was not available in 24 hr, and in one CPAP was not tolerated. lungs or focal ARDS or some cases of severe lung injury with nonrecruitable lung. Here, excessive PEEP can lead to overdistention of recruitable or healthy lungs elements (16, 17) . Although perhaps unlikely to be the full explanation at the low levels of noninvasive CPAP provided in this trial, the timing may be crucial. Our protocol prompted the use of CPAP significantly earlier in an episode of respiratory failure in the intervention group. Therefore, these relatively healthy lungs may be vulnerable to overdistension. As with all treatments, the potential for benefit or harm is influenced by the baseline risk of the population to which it is applied. CPAP may indeed be a highly effective treatment for respiratory failure in children with impaired immunity-but our data do not support its use at this very early stage. Perhaps the setting is the important difference. PICU involves significantly more intensive monitoring with higher staffing levels. It may be that earlier PICU admission results in a lower tolerance of physiologic instability and greater levels of clinical intervention which come with additional risks in a patient who is relatively well having been admitted earlier than is standard practice. This might include higher concentrations of supplemental oxygen being administered (18) or an increased frequency of intervention with risks for nosocomial infection (e.g., sedative infusions [ Table S1 , Supplemental Digital Content 3, http://links.lww.com/PCC/A720], new venous access), especially in this immunocompromised population. A third arm which analyzed CPAP administration on the ward would have been valuable in understanding this. The role of HFNC oxygen, which can be delivered on the ward more easily than CPAP, deserves consideration in this context. Of course, in healthcare systems with a lower threshold for PICU admission that would include our control group entering PICU, the risks and benefit of CPAP are likely to differ. Recent improvements in critical care have included refinements in our understanding of which patients benefit most from common interventions. Perhaps our findings concerning early CPAP can be best understood in this context (19) .
CONCLUSIONS
This RCT found no advantage for early PICU admission for CPAP in children with acute (or acute on chronic) respiratory failure in the setting of impaired immunity. There was increased early mortality associated with early PICU admission for CPAP. However, this effect was not apparent by 1 year of follow-up. 
